As medicine continues to become more personalized, manufacturers must integrate their value statements into a healthcare ecosystem burgeoning with complex and nuanced data. A one size fits all approach can no longer be employed as strategies must be tailored for specific stakeholders including payers, providers, patients, and regulatory authorities. Experts from Cardinal Health Specialty Solutions and the pharmaceutical industry explore the evolution of real-world evidence dissemination for diverse healthcare audiences.

Topics include:

  • Review of Food and Drug Administration Modernization ACT (FDAMA) 114 governing dissemination of the Health Care Economic Information (HCEI)
  • FDA framework for the use of real-world data (RWD) in regulatory decision-making
  • Updates to FDAMA uses of HCEI based on the 21st Century Cures Act
  • Examples of RWD used in promotional materials


  • Bruce Feinberg, DO, Vice President,
  • Chief Medical Officer for Cardinal Health
  • Jonathan Kish, PhD, MPH, is Senior Director-Team Lead of the Real-World Evidence and Insights, Cardinal Health
  • Nuwan Kurukulasuriya, Senior Vice President and Head, Global Medical Affairs, MorphoSys

Click here for additional information and registration details.

Related Content

Evidence Matters 2022

Evidence Matters 2022

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.